Speakers

• 

  Bob More Managing Director, Alta Partners
  

  Bob More

  Managing Director, Alta Partners

  Bob More brings over 20 years of life sciences investing experience.

  Bob currently serves on the board of Amplitude Therapeutics, Inc., Kelonia Therapeutics, MBrace Therapeutics, Tyra Biosciences (NASDAQ: TYRA), Variant Bio, and Vir Biotechnology, Inc (NASDAQ: VIR). He also manages the investment in eGenesis. He was a founding board member of the Kauffman Fellows Program and previously served on the board of BIO (Biotechnology Innovation Organization).
  Prior to Alta, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. Bob managed successful investments in and served on the boards of Affinivax (acquired by GSK), Cartiva (acquired by Wright Medical), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Glaukos Corporation (NYSE: GKOS), IntraLase (acquired by Advanced Medical Optics), Neothetics (merged with Evofem), NovaCardia (acquired by Merck), Oceana Therapeutics (acquired by Salix Pharmaceuticals) and Proxima Therapeutics (acquired by Cytyc Corporation). Bob was also an investor in Clovis Oncology (NASDAQ: CLVS), Encoded Genomics and Zeltiq Aesthetics (acquired by Allergan).

  He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.

• 

  Daniel Bradbury Managing Member, BioBrit, LLC
  

  Daniel Bradbury

  Managing Member, BioBrit, LLC

  Dan Bradbury is a Life Sciences Executive with over 40 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm based in La Jolla, CA.

  Dan is the Executive Chairman and Co-Founder of Equillium, Inc. (NASDAQ: EQ), a publicly traded biopharmaceutical company based in La Jolla, CA, focused on developing products to treat severe autoimmune and inflammatory disorders with high unmet medical need. He served as Chief Executive Officer of Equillium until January 2020. He is the former President,
  Chief Executive Officer, and Director of Amylin Pharmaceuticals, a biopharmaceutical company
  based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes, and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Before
  joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.

  Dan serves on the board of directors of Castle Biosciences, Inc. (NASDAQ: CSTL), Equillium, Inc (NASDAQ: EQ), Vivani Medical, Inc. (NASDAQ: VANI) and a number of private companies and philanthropic organizations. Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom.